# Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)

> **NCT02343939** · PHASE1,PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 148 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Entospletinib
- **DRUG:** Daunorubicin
- **DRUG:** Cytarabine
- **DRUG:** Decitabine
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT02343939
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07-01
- **Primary completion:** 2018-09-04
- **Final completion:** 2019-02-21
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2019-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02343939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02343939, "Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02343939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*